Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2006 Dec;47(12):1348-1353. Korean.
    Published online Dec 31, 2006.
    https://doi.org/10.4111/kju.2006.47.12.1348
    Copyright © 2006 The Korean Urological Association
    Original Article

    Anti-inflammatory Effect of Lycopene on Chronic Bacterial Prostatitis Rat Model

    Cho Hwan Yang, Dong Wan Sohn and Yong-Hyun Cho
      • Department of Urology, The Catholic University of Korea College of Medicine, Seoul, Korea.
    • Corresponding author (Email: cyh0831@catholic.ac.kr )
    Received June 05, 2006; Accepted July 28, 2006.

    Abstract

    Purpose

    Chronic bacterial prostatitis (CBP) is the most common urological disease in adult males, with antibiotic therapy being the gold standard for its treatment. However, long-term therapy results in many side effects as well as bacterial resistance. For these reasons, there is a need for a new treatment modality to replace traditional antibiotic therapy. Lycopene, an extract of tomatoes, has antioxidant effects against various bacteria and synergistic effects with antibiotics. We evaluate the synergistic effects of lycopene on the treatment of CBP in an animal model.

    Materials and Methods

    Forty five rats demonstrating CBP were randomly divided into 4 groups; the control, lycopene, ciprofloxacin and lycopene with ciprofloxacin groups. All drug treatments were conducted over a period of 2 weeks. After treatment, the results were analyzed, with the microbiological cultures and histological findings of the prostate and urine samples compared with the control group and between each group.

    Results

    The uses of ciprofloxacin, and lycopene with ciprofloxacin showed statistically significant decreases in bacterial growth and improvements in prostatic inflammation compared with the control group (p<0.05). The lycopene with ciprofloxacin group showed a statistically significant decrease in bacterial growth and improvements in prostatic inflammation compared with the ciprofloxacin group (p<0.05).

    Conclusions

    These results suggest that lycopene may be an effective material in the treatment of CBP. Especially, the combination treatment of lycopene and ciprofloxacin has synergistic effects. Therefore, it is suggest that the combination of lycopene and ciprofloxacin may be effective in the treatment of CBP, and with a higher success rate.

    Keywords
    Lycopene; Prostatitis; Antibiotics

    Figures

    Fig. 1
    Prostate section of a chronic bacterial prostatitis rat, obtained 2 weeks after each treatment (H&E, Bar=100µm). (A) The acinar structures are severely atrophied and obliterated. Marked chronic inflammatory cell infiltration and interstitial fibrosis are seen (Group I). (B) The acinar structures are moderately atrophied and obliterated. Moderate chronic inflammatory cell infiltration and interstitial fibrosis are seen (Group II). (C) The acinar structures are mildly shrunken, with mild lymphocytic infiltration and fibrosis in the interstitial space (Group III). (D) The acinar structures have a nearly normal appearance, with mild lymphocytic infiltration and focal fibrosis in the interstitial space (Group IV).

    Fig. 2
    Severity scores of chronic inflammatory cell infiltrations, acinar changes and interstitial fibrosis in each group. The values, expressed the means±SD, are compared with that of the control group. *: p<0.05, compared with the control group, †: p<0.05, compared with the ciprofloxacin group, SD: standard deviation.

    Tables

    Table 1
    Microbiological data of the prostate tissue and urine culture

    References

      1. Pfau A. Prostatitis. A continuing enigma. Urol Clin North Am 1986;13:695–715.
      1. Nickel JC, Olson ME, Costerton JW. Rat model of experimental bacterial prostatitis. Infection 1991;19 Suppl 3:126–130.
      1. Nickel JC. Antibiotics for bacterial prostatitis. J Urol 2000;163:1407.
      1. Ansari MS, Ansari S. Lycopene and prostate cancer. Future Oncol 2005;1:425–430.
      1. Wane D, Lengacher CA. Intergrative review of lycopene and breast cancer. Oncol Nurs Forum 2006;33:127–137.
      1. Hsiao G, Wang Y, Tzu NH, Fong TH, Shen MY, Lin KH, et al. Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation. J Lab Clin Med 2005;146:216–226.
      1. Vicari E, Rubino C, De Palma, Longo G, Lauretta M, Consoli S, et al. Antioxidant therapeutic effeciency after the use of carnitine in infertile patients with bacterial or non bacterial prostato-vesiculo-epididymitis. Arch Ital Urol Androl 2001;73:15–25.
      1. Shahed AR, Shoskes DA. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome. J Androl 2000;21:669–675.
      1. Lee YS, Shin MS, Cho YH. Experimental animal model of bacterial prostatitis. Korean J Urol 2001;42:636–641.
      1. Seo SI, Lee SJ, Kim JC, Choi YJ, Kim SW, Hwang TK, et al. Effects of androgen deprivation on chronic bacterial prostatitis in a rat model. Int J Urol 2003;10:485–491.
      1. Nickel JC, Olson ME, Barabas A, Benediktsson H, Dasgupta MK, Costerton JW. Pathogenesis of chronic bacterial prostatitis in an animal model. Br J Urol 1990;66:47–54.
      1. Cho YH, Lee SJ, Lee JY, Kim SW, Lee CB, Lee WY, et al. Antibacterial effect of intraprostatic zinc injection in a rat model of chronic bacterial prostatitis. Int J Antimicrob Agents 2002;19:576–582.
      1. Jantos C, Altmannsberger M, Weidner W, Schiefer HG. Acute and chronic bacterial prostatitis due to E-coli. Description of an animal model. Urol Res 1990;18:207–211.
      1. Moon TD. Questionnaire survey of urologist and primary care physicians' diagnostic and treatment practices for prostatitis. Urology 1997;50:543–547.
      1. Terai A, Yamamoto S, Mitsumori K, Okada Y, Kurazono H, Takeda Y, et al. Escherichia coli virulence factors and serotypes in acute bacterial prostatitis. Int J Urol 1997;4:289–294.
      1. Neal DE Jr, Moon TD. Use of terazosin in prostatodynia and validation of a symptom score questionnaire. Urology 1994;43:460–465.
      1. Winningham DG, Nemoy NJ, Stamey TA. Diffusion of antibiotics from plasma into prostatic fluid. Nature 1968;219:139–143.
      1. Stamey TA, Meares EM Jr, Winningham DG. Chronic bacterial prostatitis and diffusion of drugs into prostatic fluid. J Urol 1970;103:187–194.
      1. Herzog A, Siler U, Spitzer N, Seifert N, Denelavas A, Hunziker PB, et al. Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB J 2005;19:272–274.
      1. Kaplan SA. Lycopene: modes of action to promote prostate health. J Urol 2005;174:679.
      1. Wertz K, Siler U, Goralczyk R. Lycopene: modes of action to promote prostate health. Arch Biochem Biophys 2004;430:127–134.
      1. Reifen R, Nur T, Matas Z, Halpern Z. Lycopene supplementation attenuates the inflammatory status of colitis in a rat model. Int J Vitam Nutr Res 2001;71:347–351.
    MeSH Terms
    Adult
    Animals
    Anti-Bacterial Agents
    Antioxidants
    Bacteria
    Ciprofloxacin
    Humans
    Inflammation
    Lycopersicon esculentum
    Male
    Models, Animal*
    Prostate
    Prostatitis*
    Rats*
    Urologic Diseases
    Metrics
    Share
    Figures
    slide
    slide

    1 / 2

    Tables
    slide

    1 / 1

    PERMALINK